Janux Therapeutics
IPONovel T Cell Immunotherapies
Public · La Jolla, United States · Founded 2017 · $181.0M raised
- Headquarters
- La Jolla, California
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- januxrx.com
- Total Funding
- $181.0M
- Last Round
- $125.0M Series BApr 2021
- Rounds
- 2
- Type
- Public
About
Janux Therapeutics is a clinical-stage biopharmaceutical company developing next-generation T cell immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr) and related platforms. Its pipeline targets solid tumor cancers and autoimmune diseases, with programs including JANX014 (PSMA-targeting) currently in Phase 1 trials. The company is listed on Nasdaq (JANX) and headquartered in La Jolla, California.
Summary
Janux Therapeutics is a Biotech company based in La Jolla, United States, founded in 2017. It has raised $181.0M in total across 2 rounds, most recently a $125.0M Series B round in Apr 2021. Investors include RA Capital Management, Avalon Ventures and OrbiMed.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2021
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...